Physician profile

Sandra I Read

Dermatology · Washington, DC

NPI 1407828601

$411.52

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$203.24

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Dermavant Sciences, INC. $156.93 2023 Vtama
Pfizer INC. $55.71 2019
Abbvie INC. $46.19 2019-2023
Janssen Biotech, INC. $37.80 2020-2021
Almirall LLC $35.10 2019-2021
Incyte Corporation $31.22 2021-2022
Portola Pharmaceuticals, LLC $21.08 2020
Sun Pharmaceutical Industries INC. $15.90 2023 Blu-U, Odomzo
Ortho Dermatologics, A Division of Bausch Health US, LLC $11.59 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sandra I Read

$411.52

in general payments reported 2019-2025

Years
2019-2023
Top company
Dermavant Sciences, INC.

https://glasscript.com/doctor/545472/sandra-i-read

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.